Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study

Pulmonary Pharmacology and Therapeutics

Volumn 42, Issue , 2017, Pages 43-51

  Singh, Dave ^a   Ciurlia, Giorgia ^b   Piccinno, Annalisa ^b   Muraro, Annamaria ^b   Bocchi, Maria ^b   Scuri, Mario ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

Cardiovascular; COPD; Safety; 2 agonist

Indexed keywords

BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; GLUCOSE; IPRATROPIUM BROMIDE; PLACEBO; POTASSIUM; SALBUTAMOL; BECLOMETASONE; BRONCHODILATING AGENT; DRUG COMBINATION; FORMOTEROL FUMARATE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG FATALITY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; DRY POWDER INHALER; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; METERED DOSE INHALER; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSTATITIS; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; THERAPEUTIC EQUIVALENCE; TREMOR; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; ELECTROCARDIOGRAPHY; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SINGLE BLIND PROCEDURE;

ADMINISTRATION, INHALATION; AGED; BECLOMETHASONE; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRY POWDER INHALERS; ELECTROCARDIOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; FORMOTEROL FUMARATE; HEART RATE; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD;

EID: 85008472966     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2016.12.004     Document Type: Article

References (25)

1. [1] Müllerova, H., Agusti, A., Erqou, S., Mapel, D.W., Cardiovascular comorbidity in COPD: systematic literature review. Chest 144 (2013), 1163–1178, 10.1378/chest.12-2847.
2. [2] Limited, Chiesi, Fostair 100/6 Inhalation Solution: Summary of Product Characteristics. 2015.
3. [3] Singh, D., Corradi, M., Spinola, M., Petruzzelli, S., Papi, A., Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease. NPJ Prim. Care Respir. Med., 26, 2016, 16030, 10.1038/npjpcrm.2016.30.
4. [4] Singh, D., Nicolini, G., Bindi, E., Corradi, M., Guastalla, D., Kampschulte, J., Pierzchała, W., Sayiner, A., Szilasi, M., Terzano, C., Vestbo, J., Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD., BMC Pulm. Med, 14, 2014, 43, 10.1186/1471-2466-14-43.
5. [5] Wedzicha, J.A., Singh, D., Vestbo, J., Paggiaro, P.L., Jones, P.W., Bonnet-Gonod, F., Cohuet, G., Corradi, M., Vezzoli, S., Petruzzelli, S., Agusti, A., Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir. Med. 108 (2014), 1153–1162, 10.1016/j.rmed.2014.05.013.
6. [6] Limited, Chiesi, Fostair NEXThaler 100/6: Summary of Product Characteristics. 2015.
7. [7] Bonini, M., Usmani, O.S., The importance of inhaler devices in the treatment of COPD. COPD Res. Pract. 1 (2015), 1–9, 10.1186/s40749-015-0011-0.
8. [8] Van de Maele, B., Fabbri, L.M., Martin, C., Horton, R., Dolker, M., Overend, T., Cardiovascular safety of QVA149, a combination of indacaterol and NVA237, in COPD patients. COPD 7 (2010), 418–427, 10.3109/15412555.2010.528812.
9. [9] Ferguson, G.T., Funck-Brentano, C., Fischer, T., Darken, P., Reisner, C., Cardiovascular safety of salmeterol in COPD. Chest 123 (2003), 1817–1824, 10.1378/chest.123.6.1817.
10. [10] Drollmann, A., Brown, M., Sechaud, R., Perry, S., Hara, H., Jones, I., Febbraro, S., Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 52 (2014), 369–380, 10.5414/CP202034.
11. [11] Drollmann, A., Sechaud, R., Pal, P., Hara, H., Uziel-Fusi, S., Winkle, P., Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled study. Int. J. Clin. Pharmacol. Ther. 52 (2014), 739–745, 10.5414/CP202096.
12. [12] Khindri, S., Sabo, R., Harris, S., Woessner, R., Jennings, S., Drollmann, A.F., Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulm. Med., 11, 2011, 31, 10.1186/1471-2466-11-31.
13. [13] Edgell, H., Moore, L.E., Chung, C., Byers, B.W., Stickland, M.K., Short-term cardiovascular and autonomic effects of inhaled salbutamol. Respir. Physiol. Neurobiol. 231 (2016), 14–20, 10.1016/j.resp.2016.05.014.
14. [14] Guhan, A.R., Cooper, S., Oborne, J., Lewis, S., Bennett, J., Tattersfield, A.E., Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 55 (2000), 650–656, 10.1136/thorax.55.8.650.
15. [15] Haarmann, H., Mohrlang, C., Tschiesner, U., Rubin, D.B., Bornemann, T., Rüter, K., Bonev, S., Raupach, T., Hasenfuß, G., Andreas, S., Inhaled β-agonist does not modify sympathetic activity in patients with COPD. BMC Pulm. Med., 15, 2015, 46, 10.1186/s12890-015-0054-7.
16. [16] Salpeter, E.E., Salpeter, S.R., Ormiston, T.M., Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 125 (2004), 2309–2321, 10.1378/chest.125.6.2309.
17. [17] Santus, P., Radovanovic, D., Di Marco, S., Valenti, V., Raccanelli, R., Blasi, F., Centanni, S., Bussotti, M., Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial. Int. J. COPD 10 (2015), 1917–1923, 10.2147/COPD.S91684.
18. [18] Maesen, F.P., Costongs, R., Smeets, J.J., Brombacher, P.J., Zweers, P.G., The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations. Chest 99 (1991), 1367–1373, 10.1378/chest.99.6.1367.
19. [19] De Mey, C., Enterling, D., Meineke, I., Cardiovascular effects of eating, atenolol and their interaction: β1-adrenergic modulation does not play a predominant role in the genesis of postprandial effects. Br. J. Clin. Pharmacol. 36 (1993), 427–435, 10.1111/j.1365-2125.1993.tb00391.x.
20. ® in Patients with GOLD 2–4 chronic obstructive pulmonary disease: results of a pre-specified pooled analysis. COPD J. Chronic Obstr. Pulm. Dis. 12 (2015), 484–493, 10.3109/15412555.2014.991864.
21. [21] Vestbo, J., Anderson, J.A., Brook, R.D., Calverley, P.M.A., Celli, B.R., Crim, C., Martinez, F., Yates, J., Newby, D.E., Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 387 (2016), 1817–1826, 10.1016/S0140-6736(16)30069-1.
22. [22] Worth, H., Chung, K.F., Felser, J.M., Hu, H., Rueegg, P., Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir. Med. 105 (2011), 571–579, 10.1016/j.rmed.2010.11.027.
23. [23] Beier, J., Chanez, P., Martinot, J.-B., Schreurs, A.J.M., Tkácová, R., Bao, W., Jack, D., Higgins, M., Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm. Pharmacol. Ther. 20 (2007), 740–749, 10.1016/j.pupt.2006.09.001.
24. [24] Tzani, P., Crisafulli, E., Nicolini, G., Aiello, M., Chetta, A., Clini, E.M., Olivieri, D., Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis. 6 (2011), 503–509, 10.2147/COPD.S23746.
25. [25] Calverley, P.M.A., Kuna, P., Monsó, E., Costantini, M., Petruzzelli, S., Sergio, F., Varoli, G., Papi, A., Brusasco, V., Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir. Med. 104 (2010), 1858–1868, 10.1016/j.rmed.2010.09.008.